Feasibility and Acceptability of PREVAIL (PREserving Valued Activities In Life)

N/A Completed NCT06706999

Summary

The goal of this clinical trial is to learn if the PREVAIL model of care is a feasible way to integrate rehabilitation into routine rheumatology care for adults with rheumatoid arthritis (RA). The model of care consists of three essential components: a screening tool (Daily Activity and Participation Screen (DAPS)), a recommendation to the rheumatology clinician regarding rehabilitation referral and exercise, and an online exercise resource tailored for adults with RA. Participants will complete baseline assessments before their scheduled routine visit with a rheumatology clinician, attend their visit, receive their exercise and/or rehabilitation recommendation, and complete follow-up assessments roughly three months after their visit. Based on a participant's DAPS score, they may be recommended to complete a brief consultation call with a study physical therapist, who may or may not refer them to physical therapy (PT). Participants may also be asked to elaborate on their experience with the PREVAIL model of care in an interview.

Percentage of Participants Who Receive PREVAIL Model of Care Essential Components

Baseline assessments (including the DAPS tool) provided 1 week before routine visit, routine visit with rheumatology clinician, and 3-month follow-up assessments · percentage of participants

Percentage of Participants Who Access the Exercise Resource at Least Once During Study Duration

Collected during 3-month follow-up assessments · percentage of participants

Average Score on the Feasibility of Intervention Measure (FIM)

Collected during 3-month follow-up assessments · score on a scale

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• Dietary Salt in Rheumatoid Arthritis — Vanderbilt University Medical Center
• Long Term Extension Study to Assess the Safety and Efficacy of Filgotinib in Adults With R — Alfasigma S.p.A.
• CD40L Antagonism in Rheumatoid Arthritis (RA) — National Institute of Allergy and Infectious Diseases (NIAID)
• A Study of Baricitinib in Participants With Rheumatoid Arthritis — Eli Lilly and Company
• A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis — Eli Lilly and Company
• Long Term Follow-up of Integra® Cadence™ Total Ankle System in Primary Ankle Joint Replace — Smith & Nephew, Inc.

All trials